Reimagining Biomarkers to Illuminate the Right Patient Population & Advance Precision Medicine Impact

Time: 4:00 pm
day: Conference Day 2


  • Navigating biomarkers in cardiovascular drug development that span all modalities – genetics, peripheral proteins, lipids, inflammatory markers as well as imaging and device-derived markers
  • De-risking cardiovascular outcome trials with early proof of concept biomarkers remains a major challenge
  • Exploratory omic analyses in cardiovascular outcomes offer hypothesis generation for precision medicine